XML 57 R40.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Reportable Segment Information | The following tables show the Company’s reportable segment information for the years ended December 31, 2024, 2023 and 2022:
| December 31, 2024
| Nourish |  | H&B |  | Scent |  | Pharma |  | Total
Net sales | $ | 5,871 |  |  | $ | 2,212 |  |  | $ | 2,440 |  |  | $ | 961 |  |  | $ | 11,484 |
Cost of sales | (4,147) |  |  | (1,182) |  |  | (1,359) |  |  | (654) |  |  |
Research & development expenses | (220) |  |  | (188) |  |  | (218) |  |  | (24) |  |  |
Selling & administrative expenses | (878) |  |  | (302) |  |  | (412) |  |  | (99) |  |  |
Depreciation expense add-back (a) | 198 |  |  | 114 |  |  | 67 |  |  | 25 |  |  |
Adjusted Operating EBITDA | $ | 824 |  |  | $ | 654 |  |  | $ | 518 |  |  | $ | 209 |  |  | $ | 2,205 |
Reconciliation of Adjusted Operating EBITDA: |
Nourish | $ | 824 |
Health & Biosciences | 654 |
Scent | 518 |
Pharma Solutions | 209 |
Total | $ | 2,205 |
Depreciation & Amortization | (1,015) |
Interest Expense | (305) |
Other (Expense) Income, net (b) | (182) |
Restructuring and Other Charges (c) | (29) |
Impairment of Goodwill (d) | (64) |
Gains (Losses) on Business Disposals (f) | 346 |
Loss on Assets Classified as Held for Sale (g) | (347) |
Acquisition, Divestiture and Integration Costs (h) | (228) |
Strategic Initiatives Costs (i) | (33) |
Regulatory Costs (j) | (73) |
Other (k) | 3
Income (Loss) Before Taxes | $ | 278 |
| December 31, 2023
| Nourish |  | H&B |  | Scent |  | Pharma |  | Total
Net sales | $ | 6,060 |  |  | $ | 2,081 |  |  | $ | 2,393 |  |  | $ | 945 |  |  | $ | 11,479 |
Cost of sales | (4,517) |  |  | (1,170) |  |  | (1,400) |  |  | (698) |  |  |
Research & development expenses | (216) |  |  | (170) |  |  | (202) |  |  | (24) |  |  |
Selling & administrative expenses | (822) |  |  | (266) |  |  | (390) |  |  | (86) |  |  |
Depreciation expense add-back (a) | 227 |  |  | 113 |  |  | 60 |  |  | 62 |  |  |
Adjusted Operating EBITDA | $ | 732 |  |  | $ | 588 |  |  | $ | 461 |  |  | $ | 199 |  |  | $ | 1,980 |
Reconciliation of Adjusted Operating EBITDA: |
Nourish | $ | 732 |
Health & Biosciences | 588 |
Scent | 461 |
Pharma Solutions | 199 |
Total | $ | 1,980 |
Depreciation & Amortization | (1,142) |
Interest Expense | (380) |
Other (Expense) Income, net (b) | (5) |
Restructuring and Other Charges (c) | (68) |
Impairment of Goodwill (d) | (2,623) |
Gains (Losses) on Business Disposals (f) | (23) |
Acquisition, Divestiture and Integration Costs (h) | (174) |
Strategic Initiatives Costs (i) | (31) |
Regulatory Costs (j) | (50) |
Other (k) | (2) |
Income (Loss) Before Taxes | $ | (2,518) |
| December 31, 2022
| Nourish |  | H&B |  | Scent |  | Pharma |  | Total
Net sales | $ | 6,829 |  |  | $ | 2,339 |  |  | $ | 2,301 |  |  | $ | 971 |  |  | $ | 12,440 |
Cost of sales | (4,827) |  |  | (1,361) |  |  | (1,390) |  |  | (701) |  |  |
Research & development expenses | (211) |  |  | (166) |  |  | (189) |  |  | (23) |  |  |
Selling & administrative expenses | (853) |  |  | (282) |  |  | (353) |  |  | (81) |  |  |
Depreciation expense add-back (a) | 238 |  |  | 104 |  |  | 54 |  |  | 56 |  |  |
Adjusted Operating EBITDA | $ | 1,176 |  |  | $ | 634 |  |  | $ | 423 |  |  | $ | 222 |  |  | $ | 2,455 |
Reconciliation of Adjusted Operating EBITDA: |
Nourish | $ | 1,176 |
Health & Biosciences | 634 |
Scent | 423 |
Pharma Solutions | 222 |
Total | $ | 2,455 |
Depreciation & Amortization | (1,179) |
Interest Expense | (336) |
Other (Expense) Income, net (b) | 26 |
Restructuring and Other Charges (c) | (12) |
Impairment of Goodwill (d) | (2,250) |
Impairment of Long-Lived Assets (e) | (120) |
Gains (Losses) on Business Disposals (f) | 11 |
Acquisition, Divestiture and Integration Costs (h) | (201) |
Strategic Initiatives Costs (i) | (8) |
Other (k) | (11) |
Income (Loss) Before Taxes | $ | (1,625) |
_______________________
a | There is depreciation recorded within Cost of sales and Research, selling & administrative expenses, so there is an add-back of depreciation to calculate segment Adjusted Operating EBITDA. This reflects how the CODM reviews Segment results.
b | For 2024, the amount includes a settlement loss of $130 million that was recognized upon termination of the International Flavors & Fragrances Inc. Pension Plan. See Note 8 for additional information on the settlement loss and Note 9 for additional information on Other (Expense) Income.
c | For 2024, represents costs primarily related to the IFF Productivity Program. For 2023 and 2022, represents costs primarily related to severance as part of the Company’s restructuring efforts.
d | For 2024, represents costs related to the impairment of goodwill related to the Pharma Solutions disposal group. For 2023, represents costs related to the impairment of goodwill in the Nourish reporting unit. For 2022, represents costs related to the impairment of goodwill in the Health & Biosciences reporting unit.
e | For 2022, represents costs related to the impairment of intangible and fixed assets of an asset group that operated primarily in Russia.
f | For 2024, primarily represents gains recognized as part of the sale of the Cosmetic Ingredients business and losses recognized as part of the sale of the F&E UK business. For 2023, primarily represents losses recognized as part of the sale of the Flavors Specialty Ingredients business, the sale of a portion of the Savory Solutions business, and liquidation of a business in Russia for the sale of the portion of the Savory Solutions business. For 2022, represents gains recognized as part of the sale of the Microbial Control business.
g | For 2024, represents the losses recognized on assets classified as held for sale of the Pharma Solutions disposal group and portion of the Savory Solutions business in Turkey.
h | For 2024, 2023 and 2022, primarily represents costs related to the Company's actual and planned acquisitions and divestitures and integration activities primarily for N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For 2024, business divestiture and integration costs were approximately $223 million and $5 million, respectively. For 2023, business divestiture, integration and acquisition related costs were approximately $108 million, $59 million and $7 million, respectively. For 2022, business divestiture, integration and acquisition related costs were approximately $110 million, $94 million and credit of $(3) million, respectively.
i | Represents costs related to the Company’s strategic assessment and business portfolio optimization efforts and reorganizing the Global Shared Services Centers, primarily consulting fees, and strategic initiatives related to the Company’s business unit re-organization efforts.
j | Represents costs primarily related to legal fees incurred for the ongoing investigations of the fragrance businesses.
k | For 2024, represents costs related to the Company’s entity realignment project to optimize the structure of holding companies, primarily consulting fees, and gains from sale of assets. For 2023, represents gains from sale of assets, costs related to severance, including accelerated stock compensation expense, for a certain executive who separated from the Company in 2024. For 2022, represents gains from sale of assets, costs related to severance, including accelerated stock compensation expense, for certain employees and executives who have been separated from the Company in 2022.
Segment capital expenditures consisted as follows:
| Capital Expenditures
(DOLLARS IN MILLIONS) | 2024 |  | 2023 |  | 2022
Nourish | $ | 235 |  |  | $ | 252 |  |  | $ | 215 |
Health & Biosciences | 73 |  |  | 85 |  |  | 160 |
Scent | 70 |  |  | 62 |  |  | 56 |
Pharma Solutions | 85 |  |  | 104 |  |  | 73 |
Consolidated | $ | 463 |  |  | $ | 503 |  |  | $ | 504 |
Long-lived Assets by Geographic Areas | Long-lived assets, net, by geographic area, consisted as follows:
| December 31, |
(DOLLARS IN MILLIONS) | 2024 |  | 2023 |
United States | $ | 1,326 |  |  | $ | 1,742 |  |
Foreign Countries | 2,413 |  |  | 2,498 |  |
Consolidated | $ | 3,739 |  |  | $ | 4,240 |  |
Net Sales by Geographic Area | Net sales are attributed to individual regions based upon the destination of product delivery and are as follows:
| Net Sales by Geographic Area
(DOLLARS IN MILLIONS) | 2024 |  | 2023 |  | 2022
Europe, Africa and Middle East | $ | 3,840 |  |  | $ | 3,834 |  |  | $ | 4,219 |
Greater Asia | 2,731 |  |  | 2,677 |  |  | 2,876 |
North America | 3,440 |  |  | 3,477 |  |  | 3,853 |
Latin America | 1,473 |  |  | 1,491 |  |  | 1,492 |
Consolidated | $ | 11,484 |  |  | $ | 11,479 |  |  | $ | 12,440 |
| Net Sales by Geographic Area
(DOLLARS IN MILLIONS) | 2024 |  | 2023 |  | 2022
Net sales related to the U.S. | $ | 3,219 |  |  | $ | 3,185 |  |  | $ | 3,611 |
Net sales attributed to all foreign countries | 8,265 |  |  | 8,294 |  |  | 8,829 |

X
- Definition Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration